MORRISVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO  and a CCO, today announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of 6,000,000 shares of the Company’s common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. Syneos Health is not selling any shares and will not receive any proceeds from the sale of the shares by the selling stockholders in the Offering.

Goldman Sachs & Co. LLC and BofA Securities are acting as the underwriters of the Offering.

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.